46 of 49 eligible states, Washington DC, all eligible territories, and greater than 98 percent of litigating political subdivisions are participating in the National Settlement. Medical segment profit decreased 66% to $59 million in the third quarter, primarily due to net inflationary impacts and global supply chain constraints in products and distribution.Ĭardinal Health, along with pharmaceutical distribution peers, finalized the previously announced national opioid settlement agreement (the "National Settlement"), which became effective on April 2, 2022. Third-quarter revenue for the Medical segment decreased 7% to $3.9 billion, due to the divestiture of the Cordis business and lower products and distribution volumes, which includes the impact of global supply chain constraints. Non-GAAP diluted earnings per share (EPS) decreased 5% to $1.45, reflecting the change in non-GAAP operating earnings, partially offset by a lower non-GAAP effective tax rate and share count. Third quarter non-GAAP operating earnings decreased 21% to $545 million, primarily due to inflationary impacts and global supply chain constraints in the Medical segment. GAAP diluted loss per share was $5.05, primarily due to this impairment, net of tax effects.
Third quarter GAAP operating loss was $97 million, due to a non-cash, pre-tax goodwill impairment of $474 million in the Medical segment. Finalized the previously announced national opioid settlement agreementĭUBLIN, Ohio, / PRNewswire/ - Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2022 revenues of $44.8 billion, an increase of 14% from the third quarter of last year.Non-GAAP operating earnings decreased 21% to $545 million, primarily due to a decline in Medical segment profit Non-GAAP diluted EPS decreased 5% to $1.45.GAAP 1 operating loss was $97 million due to a non-cash, pre-tax goodwill impairment of $474 million in the Medical segment GAAP diluted loss per share was $5.05, primarily due to this impairment, net of tax effects.
0 kommentar(er)
